Table 3.

Univariate analysis of the association of clinical factors with PFS and OS

Factor	Group	n	PFS			OS
			Median survival	p value		Median survival	p-value
Age	≧64	25	8.4 (4.4–12.6)	0.319		15.1 (9.7–23.8)	0.391
	≦64	23	4.9 (3.5–11.6)			13.1 (7.6–18.5)
Gender	Female	27	8.4 (4.2–13.4)	0.297		17.4 (7.9–23.9)	0.684
	Male	21	7.1 (3.7–10.0)			14.7 (7.6–23.1)
Performance status	1,2	19	8.4 (3.7–12.6)	0.705		15.1 (7.6–18.9)	0.308
	0	29	7.1 (4.2–12.6)			15.1 (7.8-NA)
Tumor location	Body/tail	26	7.1 (4.3–9.3)	0.439		15.1 (7.6–23.8)	0.688
	Head	22	8.8 (3.7–13.4)			15.1 (7.9–18.9)
Local invasion	No	41	8.8 (4.4–12.6)	0.614		15.1 (8.0–18.5)	0.75
	Yes	7	7.9 (3.0–10.0)			18.9 (4.8–23.8)
Liver metastasis	No	30	8.1 (3.7–10.0)	0.743		14.7 (7.8–18.9)	0.284
	Yes	18	7.1 (3.6-NA)			15.1 (7.7-NA)
Lung metastasis	No	40	7.9 (4.3–9.3)	0.469		15.1 (8.0–18.9)	0.448
	Yes	8	12.6 (2.8-NA)			23.9 (5.1-NA)
Peritoneum metastasis	No	43	8.4 (4.7–10)	0.921		15.1 (9.7–23.1)	0.215
	Yes	5	4.3 (3.2-NA)			7.9 (5.5-NA)
Multiple metastasis	No	38	7.9 (4.3–12.6)	0.532		17.4 (9.3–23.8)	0.0936
	Yes	10	8.1 (1.9–11.6)			13.4 (3.4–15.1)
Chemotherapy	No	27	8.8 (4.4–12.6)	0.546		15.1 (8.0–23.1)	0.987
	Yes	21	6.8 (3.5–13.4)			15.1 (6.6–23.8)
Surgery	No	37	9.2 (4.4–12.6)	0.122		14.7 (7.9–23.1)	0.848
	Yes	11	6.8 (2.6–8.1)			15.1 (5.2–23.8)
Radiation	No	45	8.1 (4.4–11.6)	0.739		15.1 (9.3–23.1)	0.767
	Yes	3	9.3 (3.2-NA)			18.5 (6.6-NA)
GEM+nab-PTX	No	15	7.1 (3.4–11.6)	0.753		14.7 (5.5-NA)	0.959
	Yes	33	8.4 (4.4–12.6)			15.1 (9.7–23.1)
FOLFIRINOX	No	33	8.4 (4.4–12.6)	0.753		15.1 (9.7–23.1)	0.959
	Yes	15	7.1 (3.4–11.6)			14.7 (5.5-NA)
Peptide	MUC1	13	12.6 (3.0-NA)	0.415		15.1 (4.8-NA)	0.511
	WT1+ MUC1	35	7.9 (4.4–9.3)			14.7 (7.9–23.1)

Parenthesis represents a 95% confidence interval. PFS, progression free survival; OS, overall survival; GEM+nab-PTX, gemcitabine+nab-paclitaxel; FOLFIRINOX, oxaliplatin, irinotecan, fluorouracil and leucovorin. MUC1, Mucin1; WT1, Wilms’ tumor 1.